Teo, Zhi Ling
O’Connor, Mark J. http://orcid.org/0000-0003-1823-625X
Versaci, Stephanie
Clarke, Kylie A.
Brown, Emmaline R.
Percy, Luke W.
Kuykhoven, Keilly
Mintoff, Christopher P.
Savas, Peter http://orcid.org/0000-0001-5999-428X
Virassamy, Balaji http://orcid.org/0000-0002-7341-8104
Luen, Stephen J.
Byrne, Ann http://orcid.org/0000-0002-7108-7161
Sant, Sneha
Lindeman, Geoffrey J. http://orcid.org/0000-0001-9386-2416
Darcy, Phillip K.
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Article History
Received: 27 October 2021
Accepted: 7 July 2023
First Online: 15 August 2023
Competing interests
: The Authors declare the following Competing Financial and Non-Financial Interests. Sherene Loi receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, and G1 Therapeutics. Mark O’Connor is a full time employee of AstraZeneca and shareholder. Peter Savas has acted as a consultant (not compensated) for Roche-Genentech. Geoffrey Lindeman receives Investigator-Initiated Study support from AbbVie, Genentech/Roche, Pfizer and Amgen and research funding from Cancer Therapeutics-CRC (CTx). He has served on advisory boards for AbbVie and Roche. The rest of the authors declare no competing interests.